The World Health Organization (WHO)
Last month there was great news for the malaria world: A detailed analysis of the impact of insecticide-treated bednets (LLINs), ACTs, and indoor residual spraying (IRS), showed that some 6.2 million deaths and 700 million cases were averted between 2000-2015, mostly since 2005. Add up the contribution of the vector control components, and it shows that 78% of all the gains originated from just these two tools: LLINs and IRS. Is it safe to draw the conclusion from this that vector control is and shall remain the integral and critical component that will lead us to a world without malaria by 2040? I think the answer to that is 'yes, very much so'.
Mutations in the propeller domain of Plasmodium falciparum kelch 13 (Pfk13) gene are associated with artemisinin resistance in Southeast Asia.
Ensuring universal access to malaria diagnosis and treatment is a key component of Pillar 1 of the World Health Organization Global Technical Strategy for Malaria 2016–2030. To achieve this goal it is essential to know the types of facilities where the population seeks care as well as the malaria service readiness of these facilities in endemic countries.
This Cochrane Review evaluated whether more patient‐friendly alternative regimens are as efficacious as the standard regimen for radical cure ofP vivax malaria.
Indoor residual spraying (IRS), the coating of interior walls of houses with insecticides, is common in malaria-endemic areas. While important in malaria control, IRS potentially exposes residents to harmful insecticides. The World Health Organization recommends steps to minimize exposure; however, no programme has focused on educating populations.
The population pharmacokinetic models developed for both AS/DHA and MQ showed a large variability in drug exposure in the investigated African paediatric population.
This is the first study to investigate the circulation of insecticide resistance alleles in An. arabiensis from Cabo Verde.
Outcome of pregnancy and infant survival were similar between treatment arms indicating that any of the four artemisinin-based combinations could be safely used during the second and third trimester of pregnancy without any adverse effect on the baby.
Data published by the World Health Organization (WHO) when evaluating Olyset+ as well of the study of Protopopoff et al. showed that much more permethrin is available on the surface of Olyset+ than on the surface of Olyset and the relatively small and rapidly dwindling dosage of PBO may have nothing to do with the superior effect of Olyset+.